Adma Biologics (ADMA) Total Debt (2012 - 2025)

Adma Biologics' Total Debt history runs 14 years deep, the most recent figure standing at $72.1 million for Q4 2025.

• Quarterly Total Debt changed 0.27% year-over-year to $72.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $72.1 million (changed 0.27% YoY) and the FY2025 annual result came in at $72.1 million, changed 0.27% from the prior year.
• Total Debt was $72.1 million for Q4 2025 at Adma Biologics, roughly flat from $72.4 million in the prior quarter.
• Across five years, Total Debt topped out at $144.3 million in Q1 2023 and bottomed at $72.1 million in Q4 2025.
• A 5-year average of $111.1 million and a median of $116.0 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt jumped 50.56% — and 2024, when it sank 44.61%.
• Adma Biologics' Total Debt stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then retreated by 8.57% to $130.6 million in 2023, then sank by 44.61% to $72.3 million in 2024, then declined by 0.27% to $72.1 million in 2025.
• Business Quant data shows ADMA's Total Debt at $72.1 million in Q4 2025, $72.4 million in Q3 2025, and $73.4 million in Q2 2025.